Skip to content

Reimagining the infrastructure of cancer care

Solving problems for teams across the oncology ecosystem

How we partner

Transforming cancer care takes all of us. Our vision is to build a world where technology and science close the gap between care and research.

Academic Medical Centers

Enable quality care by providing evidence-based treatment options to clinicians and run more efficient clinical research by surfacing trial-eligible patients directly in the EHR. Once enrolled, digitally transfer relevant trial data from the EHR to downstream systems.

HEOR & RWE Teams

Design and execute real-world studies including comparative effectiveness, modeling long-term survival, and analyzing treatment patterns to provide insights into a treatment's long-term effectiveness as well as support market access and reimbursement decisions.

Research & Early Development Teams

Quicken drug discovery and development by linking genomics data with clinical outcomes to help assess unmet need, generate hypotheses about biomarker resistance alterations and co-alterations, and inform decision-making.

Clinical Operations Teams

Accelerate clinical research timelines, increase trial participant representativeness, and execute trials more efficiently to get your treatment to market sooner.

Regulatory Affairs Teams

Leverage Flatiron's extensive experience with regulatory-grade real-world data to develop regulatory strategies, prepare evidence packages for approval and post-market requirements, and lead regulatory engagement.

Community Oncology Practices

Deliver quality patient care with a cancer-specific EHR and surface evidence-based treatment options. For practices that support research, save time and gain accuracy through data-backed identification of eligible trial patients in the EHR and digitally transfer relevant study data seamlessly between the EHR and EDC.

Market Access Teams

Demonstrate a cancer drug's value to payers and Health Technology Assessment (HTA) bodies to accelerate access to life-extending cancer treatments worldwide and ensure reimbursement and optimal pricing.

Pharmacovigilance & Epidemiology Teams

Monitor and assess the safety of cancer drugs, leveraging retrospective and prospective real-world studies to identify adverse events, detect safety signals, and provide insights into the long-term safety profile of cancer drugs beyond clinical trials.

Contract Research Organizations

Optimize clinical trials with our novel, interoperable technology. Flatiron's products provide CROs with a streamlined, technology-driven approach to accelerate trial timelines, make data-backed decisions, and create efficiencies, giving you more confidence in trial success.

Clinical Development Teams

Utilize deep real-world data to assess the impact of inclusion/exclusion criteria and enable adjustments based on diversity goals and enrollment timelines through tailored protocol analyses that include insights on patient characteristics and expected outcomes.

Portfolio Strategy and Commercial Teams

Generate fast insights to identify portfolio gaps and opportunities, refine your commercial strategy and provide real-time line of sight into the launch performance and uptake with tailored RWE solutions.

Medical Affairs Teams

Leverage Flatiron's RWE solutions to generate insights for the scientific community, regulatory agencies, healthcare professionals, and the broader market to ensure that new drugs are developed, communicated, and utilized effectively and ethically.

New and noteworthy

featured news and insights

Explore the latest insights, research, and stories from Flatiron’s global team.

  • Harnessing the power of RWE across the NSCLC drug development lifecycle

    Cancer is often quite personal. For 42 consecutive years, cancer remained the number one reason for death in Taiwan, where I grew up. I still have memories of attending playdates as a child where the adults smoked so much that I had to leave early because I couldn’t stop coughing. Smoking was omnipresent across the country – ingrained in many daily elements. Personally, my father used to be a heavy smoker back in the day, as it was a core part of business culture. Ultimately, he quit, not for himself, but for the health of me and my sister.

    Read more
  • NCCN and Flatiron Health announce collaboration to improve cancer care quality with real-world data

    Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of their collaboration with theNational Comprehensive Cancer Network®(NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education. The collaboration between Flatiron and the NCCN dates back to 2014, when Flatiron Health first launched a cloud-based repository of NCCN Member Institution data—the NCCN Quality & Outcomes Database.

    Read more